[Cancer of Unknown Primary-The New ESMO Guidelines]

Overview

Journal Radiologie (Heidelb)

Specialty Radiology

Date 2023 Mar 17

PMID 36930265

Authors

Tilmann Bochtler

Maria Pouyiourou

Alwin Kramer

Affiliations

Soon will be listed here.

Abstract

Background: The European Society of Medical Oncology (ESMO) recently published extensively revised guidelines on cancer of unknown primary (CUP). The new version contains the following relevant amendments: with respect to diagnostics of CUP, the current guidelines aim for a more precise and standardized definition of CUP by establishing diagnostic algorithms. Recommendations for molecular diagnostics of cancer tissue have also been implemented. With respect to CUP classification, the favorable category has been revised. A carcinoma with immunohistochemistry typical for renal cell carcinoma (renal-like CUP) was introduced in the new definition of favorable subtypes, for which a specific treatment is indicated. Based on a newly defined oligometastatic situation a subgroup with localized cancer potentially curatively treatable with surgery and/or radiotherapy was introduced into the CUP classification. With respect to treatment of CUP, the current guidelines present options beyond empirical chemotherapy, which is still the standard of care treatment, and pinpoint indications and predictive biomarkers for targeted and immune checkpoint inhibitor treatment.

Relevant Updates: The European Society of Medical Oncology (ESMO) recently published extensively revised guidelines on the CUP syndrome. The new version contains the following relevant amendments: the current guidelines aim for a more precise and standardized definition of CUP by establishing diagnostic algorithms with respect to the diagnostics of CUP syndrome. Recommendations for molecular diagnostics of cancer tissue have also been implemented. The classification of the CUP syndrome has also been revised. A carcinoma with immunohistochemistry typical for renal cell carcinoma (renal-like CUP) was introduced in the new definition of favorable subtypes, for which a specific treatment is indicated. Based on a newly defined oligometastatic situation a local potentially curatively treatable with surgery and/or radiotherapy subgroup was introduced into the CUP classification. With respect to treatment of the CUP syndrome, the current guidelines present options beyond empirical chemotherapy, which is still the gold standard treatment, and pinpoint indications and predictive biomarkers for targeted and immune checkpoint inhibitor treatment.

Schlussfolgerung: The aim of this review is to present the current state of diagnostics, classification and treatment of CUP syndrome, with a focus on recent developments and revisions implemented in the current ESMO guidelines.

References

Fizazi K, Greco F, Pavlidis N, Daugaard G, Oien K, Pentheroudakis G . Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26 Suppl 5:v133-8. DOI: 10.1093/annonc/mdv305. View

Kramer A, Bochtler T, Pauli C, Baciarello G, Delorme S, Hemminki K . Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022; 34(3):228-246. DOI: 10.1016/j.annonc.2022.11.013. View

Kwee T, Kwee R . Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol. 2008; 19(3):731-44. PMC: 2816234. DOI: 10.1007/s00330-008-1194-4. View

Albertson M, Chandra S, Sayed Z, Johnson C . PET/CT Evaluation of Head and Neck Cancer of Unknown Primary. Semin Ultrasound CT MR. 2019; 40(5):414-423. DOI: 10.1053/j.sult.2019.07.005. View

Maghami E, Ismaila N, Alvarez A, Chernock R, Duvvuri U, Geiger J . Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck: ASCO Guideline. J Clin Oncol. 2020; 38(22):2570-2596. DOI: 10.1200/JCO.20.00275. View

Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I . Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiother Oncol. 2020; 148:157-166. DOI: 10.1016/j.radonc.2020.04.003. View

Pauli C, Bochtler T, Mileshkin L, Baciarello G, Losa F, Ross J . A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience. Oncologist. 2021; 26(5):e769-e779. PMC: 8100559. DOI: 10.1002/onco.13744. View

Bochtler T, Endris V, Leichsenring J, Reiling A, Neumann O, Volckmar A . Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome. Int J Cancer. 2019; 145(11):2963-2973. DOI: 10.1002/ijc.32316. View

Pouyiourou M, Wohlfromm T, Kraft B, Hielscher T, Stichel D, von Deimling A . Local ablative treatment with surgery and/or radiotherapy in single-site and oligometastatic carcinoma of unknown primary. Eur J Cancer. 2021; 157:179-189. DOI: 10.1016/j.ejca.2021.08.019. View

10.

Varadhachary G, Raber M, Matamoros A, Abbruzzese J . Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions. Lancet Oncol. 2008; 9(6):596-9. DOI: 10.1016/S1470-2045(08)70151-7. View

11.

Hainsworth J, Schnabel C, Erlander M, Haines 3rd D, Greco F . A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile. Clin Colorectal Cancer. 2011; 11(2):112-8. DOI: 10.1016/j.clcc.2011.08.001. View

12.

Greco F, Hainsworth J . Renal Cell Carcinoma Presenting as Carcinoma of Unknown Primary Site: Recognition of a Treatable Patient Subset. Clin Genitourin Cancer. 2018; 16(4):e893-e898. DOI: 10.1016/j.clgc.2018.03.001. View

13.

Overby A, Duval L, Ladekarl M, Laursen B, Donskov F . Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature. Clin Genitourin Cancer. 2018; 17(1):e32-e37. DOI: 10.1016/j.clgc.2018.08.005. View

14.

Golfinopoulos V, Pentheroudakis G, Salanti G, Nearchou A, Ioannidis J, Pavlidis N . Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis. Cancer Treat Rev. 2009; 35(7):570-3. DOI: 10.1016/j.ctrv.2009.05.005. View

15.

Lee J, Hahn S, Kim D, Kim J, Kang S, Rha S . Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis. Br J Cancer. 2012; 108(1):39-48. PMC: 3553519. DOI: 10.1038/bjc.2012.516. View

16.

Huebner G, Link H, Kohne C, Stahl M, Kretzschmar A, Steinbach S . Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. Br J Cancer. 2008; 100(1):44-9. PMC: 2634671. DOI: 10.1038/sj.bjc.6604818. View

17.

Gross-Goupil M, Fourcade A, Blot E, Penel N, Negrier S, Culine S . Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomised GEFCAPI 02 trial. Eur J Cancer. 2012; 48(5):721-7. DOI: 10.1016/j.ejca.2012.01.011. View

18.

Culine S, Lortholary A, Voigt J, Bugat R, Theodore C, Priou F . Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol. 2003; 21(18):3479-82. DOI: 10.1200/JCO.2003.12.104. View

19.

Seto T, Azuma K, Yamanaka T, Sugawara S, Yoshioka H, Wakuda K . Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L). J Clin Oncol. 2019; 38(8):793-803. DOI: 10.1200/JCO.19.01494. View

20.

Ross J, Wang K, Gay L, Otto G, White E, Iwanik K . Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies. JAMA Oncol. 2015; 1(1):40-49. DOI: 10.1001/jamaoncol.2014.216. View